Top Markets
#1 EXOD EXOD +22.08%
#2 Geodnet Geodnet +17.63%
#3 Ontology Gas Ontology Gas +17.44%
#4 XPIN Network XPIN Network +17.03%
#5 Derive Derive +15.73%
#6 Status Status +13.62%
#7 Neiro Neiro +12.53%
#8 Pons Pons +12.37%
#9 Collect on Fanable Collect on Fanable +11.77%
#10 AUKI AUKI +9.94%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Classifica tra le azioni #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Prezzo delle azioni
$23.57
Ultima sincronizzazione: 2026-08-20
Capitalizzazione di mercato
$51.76M
Variazione (1 giorno)
-0.08%
Variazione (1 anno)
289.59%
Paese
US
Scambia Apollomics, Inc. (APLM)

Categoria

Healthcare
Utile per Apollomics, Inc. (APLM)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Apollomics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Apollomics, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US